Kintor Pharmaceutical 将来の成長

Future 基準チェック /26

Kintor Pharmaceuticalは、25.8%と160%でそれぞれ年率25.8%で利益と収益が成長すると予測される一方、EPSはgrowで27.8%年率。

主要情報

25.8%

収益成長率

27.8%

EPS成長率

Biotechs 収益成長	42.2%
収益成長率	160.0%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	16 Oct 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

SEHK:9939 - アナリストの将来予測と過去の財務データ ( )CNY Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2025	388	-615	-597	-1,016	1
12/31/2024	103	-800	-824	-1,145	1
6/30/2024	N/A	-920	-287	-284	N/A
3/31/2024	N/A	-991	-339	-336	N/A
12/31/2023	N/A	-1,061	-390	-388	N/A
9/30/2023	N/A	-854	-437	-427	N/A
6/30/2023	N/A	-648	-484	-467	N/A
3/31/2023	N/A	-801	-736	-714	N/A
12/31/2022	N/A	-954	-989	-961	N/A
9/30/2022	17	-995	-1,192	-1,144	N/A
6/30/2022	34	-1,035	-1,396	-1,328	N/A
3/31/2022	34	-938	-1,276	-1,190	N/A
12/31/2021	34	-842	-1,157	-1,051	N/A
9/30/2021	17	-740	-960	-851	N/A
6/30/2021	N/A	-639	-763	-650	N/A
3/31/2021	N/A	-573	-620	-516	N/A
12/31/2020	N/A	-508	-477	-381	N/A
9/30/2020	N/A	-419	-430	-341	N/A
6/30/2020	N/A	-330	-382	-301	N/A
3/31/2020	N/A	-281	-342	-264	N/A
12/31/2019	N/A	-233	-302	-228	N/A
12/31/2018	1	-108	-134	-115	N/A
12/31/2017	0	-46	N/A	-45	N/A
9/30/2017	0	-41	N/A	-36	N/A
6/30/2017	0	-35	N/A	-27	N/A
3/31/2017	1	-45	N/A	-21	N/A
12/31/2016	1	-54	N/A	-15	N/A
12/31/2015	N/A	-11	N/A	-13	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 9939今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 9939今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: 9939今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 9939の収益 ( 160% ) Hong Kong市場 ( 7.8% ) よりも速いペースで成長すると予測されています。

高い収益成長: 9939の収益 ( 160% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 9939の自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Kintor Pharmaceutical 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Forecast to breakeven in 2023

Consensus revenue estimates fall by 98%

Forecast breakeven date pushed back to 2023

Forecast breakeven date pushed back to 2023

Consensus forecasts updated

Recent updates

New major risk - Revenue and earnings growth

Founder recently bought HK$107k worth of stock

Kintor Pharmaceutical Limited Receives Review Approval of Incorporation for KT-939

Kintor Pharmaceutical Limited Announces Completion of First Subject Enrollment in Pivotal Clinical Trial of Kx-826 Tincture 1.0% for the Treatment of Men Adult Androgenetic Alopecia in China

Founder recently bought HK$248k worth of stock

Is Kintor Pharmaceutical (HKG:9939) Using Debt In A Risky Way?

Founder recently bought HK$249k worth of stock

Founder recently bought HK$424k worth of stock

Kintor Pharmaceutical Limited to Report First Half, 2024 Results on Aug 26, 2024

Founder recently bought HK$294k worth of stock

Kintor Pharmaceutical Limited Announces Completion of First Subject Enrollment in Phase II Clinical Trial of GT20029 Gel for Treatment of Ance in China

Kintor Pharmaceutical Limited, Annual General Meeting, Jun 20, 2024

Kintor Pharmaceutical Limited Announces Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China Reaches Primary Endpoint

Kintor Pharmaceutical Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

New major risk - Share price stability

Kintor Pharmaceutical Limited Announces Phase Ib/III Clinical Trial of KX-826 and Minoxidil Combination Therapy for the Treatment of Men Adults Receives Clearance by China NMPA

Founder recently bought HK$774k worth of stock

Kintor Pharmaceutical Limited Announces Results of Phase III Clinical Trial of KX-826 Topline Treatment for Men Androgenetic Alopecia

Kintor Pharmaceutical Limited Announces Results of Phase III Clinical Trial of KX-826 Topline Treatment for Men Androgenetic Alopecia

New minor risk - Share price stability

Does Kintor Pharmaceutical (HKG:9939) Have A Healthy Balance Sheet?

New major risk - Financial position

Kintor Pharmaceutical Limited Announces the Approval for Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China

Insider recently sold HK$2.6m worth of stock

Insider recently sold HK$42m worth of stock

New major risk - Revenue and earnings growth

Kintor Pharma Announces Completion of Patient Enrollment in Phase Ii Clinical Trial of Gt20029 for Treatment of Androgenetic Alopecia in China

Kintor Pharmaceutical Limited to Report First Half, 2023 Results on Aug 28, 2023

Kintor Pharmaceutical Limited Announces Completion of First Patient Enrollment in Long-Term Safety Trial of Kx-826

Kintor Pharmaceutical Limited, Annual General Meeting, Jun 15, 2023

Kintor Pharmaceutical Limited Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US

Kintor Pharmaceutical Limited Announces Successful Completion of Phase I Clinical Trial of GT1708F for Treatment of Hematological Malignancies in China

Insider recently sold HK$12m worth of stock

Forecast to breakeven in 2023

Kintor Pharmaceutical Limited Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World's First Topical Use PROTAC Compound

Kintor Pharmaceutical Limited has completed a Follow-on Equity Offering in the amount of HKD 517.6 million.

Kintor Pharmaceutical Limited Announces the Primary Endpoint of Phase II Clinical Study for KX-826's Treatment of Female Androgenetic Alopecia in China Was Met

Kintor Pharmaceutical Limited Announces Top-Line Results of Phase I Clinical Trial of Gt20029 in China

Less than half of directors are independent

Kintor Pharmaceutical Limited Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of Gt20029 in the U.S

Kintor Pharmaceutical Limited Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX 826 for Acne Vulgaris in China

Kintor Pharmaceutical Limited Announces Publication of Phase Ib Data from Pruxelutamide for Ar+ Mbc in Ejc

Consensus revenue estimates fall by 98%

Kintor Pharmaceutical Limited to Report First Half, 2022 Results on Aug 29, 2022

Kintor Pharmaceutical Limited Completes Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in China

Kintor Pharmaceutical Limited Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the Us

Key Executive recently sold HK$5.7m worth of stock

Kintor Pharmaceutical Limited, Annual General Meeting, Jun 30, 2022

Insider recently sold HK$60m worth of stock

Kintor Pharmaceutical Limited Announces Board Changes

Kintor Pharmaceutical Limited Announces First Patient Dosing in Multi-Regional Global Phase II Clinical Trial of ALK-1 Antibody and Nivolumab Combination Therapy for the Treatment of Advanced Hepatocellular Carcinoma

Forecast breakeven date pushed back to 2023

Does Kintor Pharmaceutical (HKG:9939) Have A Healthy Balance Sheet?

Less than half of directors are independent

Kintor Pharmaceutical Limited Announces Top-Line Results of the Phase III MRCT of Proxalutamide in Outpatients with Mild to Moderate Covid-19

Forecast breakeven date pushed back to 2023

Kintor Pharmaceutical Limited Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 in China for the Treatment of Aga in Female Patients

Kintor Pharma Limited Announces First Patient Dosing in Phase II Clinical Trial of KX-826 for Treatment of Androgenic Alopecia Patients in the US

Kintor Pharmaceutical Limited Announces Executive Changes

Kintor Pharma Announces First Patient Dosing in China in Phase III Clinical Trial of Proxalutamide for the Treatment of COVID-19 Outpatients

Kintor Pharmaceutical Limited Announces Dosing of First Subject in US Phase I Clinical Trial of GT20029 for Androgenic Alopecia and Acne

Kintor Pharma Announces Successful Dosing of the First Patient for Acne Vulgaris Phase II Clinical Trial of KX-826

Kintor Pharmaceutical Limited Announces First Patient Dosing of Phase III Clinical Trial of KX-826 (Pyrilutamide) for Treating Androgenic Alopecia Patients in China

Kintor Pharmaceutical Limited Provides Update Interim Analysis for Phase III Study of Proxalutamide for Patients with Mild to Moderate Covid-19 Symptoms

Does Kintor Pharmaceutical (HKG:9939) Have A Healthy Balance Sheet?

Deputy GM & Joint Company Secretary Jie Chen has left the company

Non-Executive Director Wei Zhang has left the company

Kintor Pharmaceutical Limited Receives IND Clearance by NMPA for KX-826

Kintor Pharmaceutical Limited Announces the Phase III Clinical Trial of Proxalutamide for the Treatment of Hospitalized Covid-19 Patients

Non-Executive Director recently bought HK$4.3m worth of stock